title: A novel class of small molecule inhibitors of Hsp90.
abstract: Unregulated cellular proliferation, caused by mutation or dysregulation of growth-promoting proteins, is an underlying cause of cancer. Many such growth-promoting proteins exhibit an increased dependence on the activity of the chaperone heat-shock protein 90 (Hsp90) for correct folding and maturation in the cell. One can therefore envision that inhibition of Hsp90 would be an effective and broadly applicable strategy for the development of anticancer agents. Hsp90 functions in multichaperone complexes driven by the binding and hydrolysis of ATP. Encouraging results have been obtained by inhibiting Hsp90 with 17-AAG, an active-site binding ATP analog. Here we present the results of a different approach to inhibiting Hsp90 by disrupting its interaction with a cochaperone named Hsp organizing protein (HOP). We have used an AlphaScreen technology based high-throughput in vitro screen to identify compounds that inhibit this interaction. In addition, we demonstrate that these compounds are active in vivo. Treatment of human breast cancer cell lines BT474 and SKBR3 with these compounds decreases the levels of the Hsp90-dependent client protein HER2, with associated cell death.
authors.affiliation: Department of Molecular Biophysics & Biochemistry, Yale University, 266 Whitney Avenue, New Haven, Connecticut 06520, USA.
authors.forename: Fang
authors.initials: F
authors.lastname: Yi
authors.forename: Lynne
authors.initials: L
authors.lastname: Regan
mesh_terms: D016588:Anticarcinogenic Agents / Q000737:chemistry* / Q000494:pharmacology*; D016227:Benzoquinones / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D047029:Lactams, Macrocyclic / Q000737:chemistry / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D016588:Anticarcinogenic Agents; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D018719:Erb-b2 Receptor Tyrosine Kinases; C112765:tanespimycin
references.citation: J Biol Chem. 1998 Dec 25;273(52):35194-200
references.pmid: 9857057
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1769-74
references.pmid: 17363531
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: FEBS Lett. 2007 Jul 31;581(19):3758-69
references.pmid: 17559840
references.citation: Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324-8
references.pmid: 8078881
references.citation: Cancer Res. 2002 Jul 15;62(14):4132-41
references.pmid: 12124352
references.citation: Chem Pharm Bull (Tokyo). 1975 Sep;23(9):2001-9
references.pmid: 171091
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1775-82
references.pmid: 17363532
references.citation: ACS Chem Biol. 2008 Mar 20;3(3):161-6
references.pmid: 18355005
references.citation: J Biosci. 2007 Apr;32(3):517-30
references.pmid: 17536171
references.citation: Nat Protoc. 2006;1(2):550-3
references.pmid: 17191086
references.citation: Cell Cycle. 2003 Nov-Dec;2(6):579-84
references.pmid: 14512773
references.citation: Curr Med Chem. 2007;14(29):3122-38
references.pmid: 18220746
references.citation: J Mol Biol. 2008 Jun 13;379(4):732-44
references.pmid: 18485364
references.citation: J Biol Chem. 2005 Nov 18;280(46):38729-39
references.pmid: 16172114
references.citation: Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15422-7
references.pmid: 17032757
references.citation: Ann Oncol. 2008 Feb;19(2):269-75
references.pmid: 17998285
references.citation: Nat Med. 2000 Apr;6(4):443-6
references.pmid: 10742152
references.citation: Ann Oncol. 2001;12 Suppl 1:S23-8
references.pmid: 11521717
references.citation: Carbohydr Res. 2007 Jul 2;342(9):1254-60
references.pmid: 17412311
references.citation: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references.pmid: 4202581
references.citation: Cell. 2000 Apr 14;101(2):199-210
references.pmid: 10786835
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4152-61
references.pmid: 15961763
references.citation: Trends Endocrinol Metab. 1998 Aug;9(6):244-52
references.pmid: 18406276
references.citation: Cancer Res. 2001 May 15;61(10):4003-9
references.pmid: 11358818